Kymera Therapeutics (KYMR) Current Leases (2019 - 2025)
Historic Current Leases for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $11.9 million.
- Kymera Therapeutics' Current Leases rose 299.79% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year increase of 299.79%. This contributed to the annual value of $11.6 million for FY2024, which is 12876.87% up from last year.
- Per Kymera Therapeutics' latest filing, its Current Leases stood at $11.9 million for Q3 2025, which was up 299.79% from $11.8 million recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' Current Leases registered a high of $11.9 million during Q3 2025, and its lowest value of $2.4 million during Q1 2021.
- Over the past 5 years, Kymera Therapeutics' median Current Leases value was $2.6 million (recorded in 2023), while the average stood at $5.8 million.
- Its Current Leases has fluctuated over the past 5 years, first crashed by 1061.11% in 2021, then soared by 34520.65% in 2024.
- Kymera Therapeutics' Current Leases (Quarter) stood at $2.5 million in 2021, then rose by 3.01% to $2.5 million in 2022, then soared by 99.92% to $5.1 million in 2023, then soared by 128.77% to $11.6 million in 2024, then grew by 2.23% to $11.9 million in 2025.
- Its last three reported values are $11.9 million in Q3 2025, $11.8 million for Q2 2025, and $11.7 million during Q1 2025.